Monitoring of HCV infected patients on the waiting list for kidney transplantation

Surveillance of HCV-infected kidney transplant candidates is the organized monitoring of infection status, liver injury, treatment response, and overall transplant suitability while patients remain on the kidney waiting list. It converts a single pretransplant assessment into a longitudinal process: candidates are screened for active HCV infection, followed for fibrosis progression and relapse, reassessed for cardiovascular and metabolic risk, and removed from kidney-alone pathways if cirrhosis makes another transplant strategy more appropriate.

Entry Into Surveillance

Patients who have not previously been tested should undergo screening for anti-HCV antibodies, with positive results confirmed by nucleic acid testing in low-prevalence regions; in high-prevalence settings, testing may proceed directly with nucleic acid testing. A positive NAT identifies active viremia and should trigger hold status on the waiting list, referral to a hepatologist, and evaluation for possible antiviral treatment. This distinction is essential because anti-HCV positivity alone does not establish ongoing infection: chronic infection requires both anti-HCV antibodies and detectable HCV RNA, whereas absent RNA indicates resolved infection or recovery.

The initial evaluation must also determine how far the infection has affected the liver and other organs. Active infection requires staging of liver disease, and liver biopsy remains the gold standard during the pretransplant evaluation, even though noninvasive tools such as FibroScan and biochemical fibrosis scores can reduce the need for biopsy in other settings. The reason for this caution is substantial: studies found advanced liver injury, including stage 3 or 4 fibrosis and cirrhosis, in approximately 10–25% of candidates when biopsies were performed. Established or decompensated cirrhosis changes the destination of care; such patients should be referred to a liver transplant team for consideration of simultaneous liver–kidney transplantation rather than proceeding automatically toward kidney-alone transplantation.

Monitoring While Listed

A patient who has achieved a sustained virologic response before transplantation should still undergo NAT at least annually to confirm that the response remains durable. If relapse occurs, the candidate should be placed on hold and referred to a hepatologist for consideration of retreatment. Patients who remain viremic while listed require annual assessment to determine whether liver disease has advanced during the wait. This continuing review is particularly important in parts of the United States where waiting times for a deceased-donor kidney approach five to seven years.

The surveillance schedule is tied to the severity of fibrosis. Patients whose pretransplant biopsy shows Metavir stage 1 or 2 fibrosis should undergo repeat liver biopsy every five years. Those with stage 3 fibrosis require closer observation and repeat biopsy after three years. Progression during dialysis is not theoretical: among 13 candidates who underwent repeat biopsy while still on the waiting list, eight, or 62%, showed worsening liver histology. By contrast, only seven of 31, or 23%, of post-transplant follow-up biopsies showed interval worsening in the cited comparison. If the disease progresses to early or established cirrhosis, the patient should be removed from the kidney waiting list and referred for evaluation of simultaneous liver–kidney transplantation.

Risk Beyond the Liver

Monitoring cannot be limited to fibrosis. HCV infection is a systemic disease capable of producing renal, autoimmune, dermatological, and vascular complications, including mixed cryoglobulinemia and cryoglobulinemia-associated vasculitis. The latter may involve purpura, arthralgias, neuropathy, hypocomplementemia, proteinuria, hematuria, and cryoglobulinemic glomerulonephritis. These manifestations can precede kidney disease by years, so surveillance must preserve attention to extrahepatic symptoms even when liver enzyme abnormalities are mild.

Death on the waiting list is another competing outcome. In the United States, the overall death rate for patients on kidney waiting lists is approximately 6–7%, with cardiovascular disease the leading contributor. In a single-center study of HCV-infected kidney candidates, diabetes was significantly more prevalent among infected patients and was the only usual clinical variable associated with death in a Cox regression model, with a hazard ratio of 2.17 and a 95% confidence interval of 1.1–4.1. Liver disease was not predictive of mortality in that model. Accordingly, surveillance should include robust cardiovascular assessment and attention to diabetes rather than treating hepatic progression as the sole determinant of waiting-list risk.

Treatment and Transplant Decisions

There is no universal consensus on treating an actively viremic candidate before transplantation, but achieving a sustained virologic response before transplantation is generally desirable. Available evidence suggests that most patients who achieve such a response do not relapse after immunosuppression, and pretransplant viral clearance may reduce the risk of post-transplant diabetes and immune-complex glomerular disease in the allograft. The effect on subsequent progression of liver injury is less certain, so surveillance remains necessary even after successful treatment.

The timing of therapy is also shaped by safety. Interferon use after transplantation has been associated with an increased risk of renal-allograft rejection, which means that efforts to eradicate HCV are preferably concentrated before transplantation. Yet treatment may be prolonged, expensive, poorly tolerated, or ineffective; adverse events are common, some patients refuse or withdraw, and others fail to respond. Antiviral treatment may also require temporary exclusion from the waiting list, increasing the cost of pursuing virologic clearance when a kidney is urgently needed.

For candidates who cannot undergo or do not achieve antiviral treatment, continued dialysis may carry greater danger than transplantation despite persistent HCV RNA. In this setting, transplantation with a kidney from an HCV-positive donor may be offered, potentially reducing waiting time. The decision must balance transmission and graft considerations against the risks of remaining on dialysis, while recognizing that HCV-positive kidneys are frequently discarded: one analysis found them 2.60 times more likely to be discarded than HCV-negative kidneys. Surveillance therefore functions not only as disease follow-up but also as the clinical mechanism by which a candidate's changing infection status, liver stage, treatment response, mortality risk, and access to an organ are brought into one decision.

Institutional Framework and Significance

The process reflects a broader shift from a one-time eligibility judgment to governance across the waiting period. Screening, NAT confirmation, biopsy intervals, hold status, specialist referral, annual reassessment, and removal from the list establish successive classifications through which an HCV-infected body becomes administratively visible and clinically manageable. The same framework also separates antibody evidence from active viremia, liver fibrosis from cirrhosis, and kidney-alone transplantation from combined-organ transplantation, preventing a laboratory result from being treated as a complete account of disease.

At the population level, this surveillance is part of the response to the changing epidemiology of HCV in chronic kidney disease, dialysis, and transplantation. Improved blood safety, preventive strategies, and antiviral therapy have reduced active infection among patients with end-stage renal disease, while organ shortages continue to lengthen waiting times and make the efficient use of HCV-positive donor kidneys a pressing issue. The surveillance of HCV-infected kidney transplant candidates thus links virology, pathology, treatment toxicity, transplant allocation, and survival: it protects candidates from undergoing an unsuitable kidney-alone transplant, but it also seeks to prevent prolonged waiting and dialysis from becoming the default consequence of infection.